View Future GrowthPharmigene 과거 순이익 실적과거 기준 점검 0/6Pharmigene 의 수입은 연평균 -20.7%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 22.5%의 비율로 증가했습니다. 매출은 연평균 8.9%의 비율로 증가해 왔습니다.핵심 정보-20.74%순이익 성장률-17.38%주당순이익(EPS) 성장률Biotechs 산업 성장률12.22%매출 성장률8.87%자기자본이익률-20.08%순이익률-27.82%최근 순이익 업데이트30 Jun 2026최근 과거 실적 업데이트Reported Earnings • Aug 15First half 2025 earnings released: NT$0.82 loss per share (vs NT$0.96 loss in 1H 2024)First half 2025 results: NT$0.82 loss per share (improved from NT$0.96 loss in 1H 2024). Revenue: NT$80.7m (up 68% from 1H 2024). Net loss: NT$41.3m (loss narrowed 15% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.64 loss per share (vs NT$1.60 loss in FY 2023)Full year 2024 results: NT$1.64 loss per share (further deteriorated from NT$1.60 loss in FY 2023). Revenue: NT$116.5m (down 12% from FY 2023). Net loss: NT$82.9m (loss widened 14% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 18First half 2024 earnings released: NT$0.96 loss per share (vs NT$0.66 loss in 1H 2023)First half 2024 results: NT$0.96 loss per share (further deteriorated from NT$0.66 loss in 1H 2023). Revenue: NT$47.9m (down 11% from 1H 2023). Net loss: NT$48.7m (loss widened 70% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • May 04Full year 2023 earnings released: NT$1.60 loss per share (vs NT$0.98 loss in FY 2022)Full year 2023 results: NT$1.60 loss per share (further deteriorated from NT$0.98 loss in FY 2022). Revenue: NT$132.7m (flat on FY 2022). Net loss: NT$72.6m (loss widened 70% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 14First half 2023 earnings released: NT$0.66 loss per share (vs NT$0.53 loss in 1H 2022)First half 2023 results: NT$0.66 loss per share (further deteriorated from NT$0.53 loss in 1H 2022). Revenue: NT$53.6m (down 2.7% from 1H 2022). Net loss: NT$28.7m (loss widened 25% from 1H 2022).Reported Earnings • Apr 07Full year 2022 earnings released: NT$0.98 loss per share (vs NT$0.54 loss in FY 2021)Full year 2022 results: NT$0.98 loss per share (further deteriorated from NT$0.54 loss in FY 2021). Revenue: NT$133.8m (up 3.4% from FY 2021). Net loss: NT$42.7m (loss widened 82% from FY 2021).모든 업데이트 보기Recent updatesNew Risk • Jul 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$76m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$408.8m market cap, or US$12.7m).New Risk • Jul 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$316.9m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$76m free cash flow). Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (NT$316.9m market cap, or US$9.83m).Board Change • Mar 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Jan 30Pharmigene, Inc., Annual General Meeting, Jun 15, 2026Pharmigene, Inc., Annual General Meeting, Jun 15, 2026. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city TaiwanNew Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$86m free cash flow). Earnings have declined by 35% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (NT$149m revenue, or US$4.9m). Market cap is less than US$100m (NT$570.3m market cap, or US$18.8m).Reported Earnings • Aug 15First half 2025 earnings released: NT$0.82 loss per share (vs NT$0.96 loss in 1H 2024)First half 2025 results: NT$0.82 loss per share (improved from NT$0.96 loss in 1H 2024). Revenue: NT$80.7m (up 68% from 1H 2024). Net loss: NT$41.3m (loss narrowed 15% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Board Change • Jun 23Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.64 loss per share (vs NT$1.60 loss in FY 2023)Full year 2024 results: NT$1.64 loss per share (further deteriorated from NT$1.60 loss in FY 2023). Revenue: NT$116.5m (down 12% from FY 2023). Net loss: NT$82.9m (loss widened 14% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.공고 • Mar 12Pharmigene, Inc., Annual General Meeting, Jun 03, 2025Pharmigene, Inc., Annual General Meeting, Jun 03, 2025. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city TaiwanNew Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$143m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (NT$127m revenue, or US$3.9m). Market cap is less than US$100m (NT$683.8m market cap, or US$20.8m).Reported Earnings • Aug 18First half 2024 earnings released: NT$0.96 loss per share (vs NT$0.66 loss in 1H 2023)First half 2024 results: NT$0.96 loss per share (further deteriorated from NT$0.66 loss in 1H 2023). Revenue: NT$47.9m (down 11% from 1H 2023). Net loss: NT$48.7m (loss widened 70% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • May 04Full year 2023 earnings released: NT$1.60 loss per share (vs NT$0.98 loss in FY 2022)Full year 2023 results: NT$1.60 loss per share (further deteriorated from NT$0.98 loss in FY 2022). Revenue: NT$132.7m (flat on FY 2022). Net loss: NT$72.6m (loss widened 70% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.공고 • Apr 12Pharmigene, Inc., Annual General Meeting, Jun 24, 2024Pharmigene, Inc., Annual General Meeting, Jun 24, 2024.New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.03b market cap, or US$32.6m).New Risk • Oct 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.1m). Market cap is less than US$100m (NT$1.16b market cap, or US$35.9m).Reported Earnings • Aug 14First half 2023 earnings released: NT$0.66 loss per share (vs NT$0.53 loss in 1H 2022)First half 2023 results: NT$0.66 loss per share (further deteriorated from NT$0.53 loss in 1H 2022). Revenue: NT$53.6m (down 2.7% from 1H 2022). Net loss: NT$28.7m (loss widened 25% from 1H 2022).New Risk • Aug 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$681m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.06b market cap, or US$33.4m).Reported Earnings • Apr 07Full year 2022 earnings released: NT$0.98 loss per share (vs NT$0.54 loss in FY 2021)Full year 2022 results: NT$0.98 loss per share (further deteriorated from NT$0.54 loss in FY 2021). Revenue: NT$133.8m (up 3.4% from FY 2021). Net loss: NT$42.7m (loss widened 82% from FY 2021).Reported Earnings • Apr 12Full year 2021 earnings released: NT$0.54 loss per share (vs NT$0.33 loss in FY 2020)Full year 2021 results: NT$0.54 loss per share (down from NT$0.33 loss in FY 2020). Revenue: NT$129.4m (up 28% from FY 2020). Net loss: NT$23.4m (loss widened 109% from FY 2020).매출 및 비용 세부 내역Pharmigene가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TPEX:7595 매출, 비용 및 순이익 (TWD Millions)날짜매출순이익일반관리비연구개발비30 Jun 26188-52712631 Mar 26194-63713331 Dec 25200-73714130 Sep 25175-74753930 Jun 25149-76793731 Mar 25133-79883331 Dec 24117-83973030 Sep 24122-88943030 Jun 24127-93903031 Mar 24130-83813031 Dec 23133-73713030 Sep 23133-61673230 Jun 23132-48643331 Mar 23133-46623231 Dec 22134-43593030 Sep 22129-40592630 Jun 22125-37582231 Mar 22127-30561931 Dec 21129-23531530 Sep 21120-20521230 Jun 21110-1652931 Mar 21106-1351931 Dec 20101-1149930 Sep 2097-1948930 Jun 2092-2747931 Mar 2079-31441131 Dec 1965-35411231 Dec 1878-13291131 Dec 1755-8168양질의 수익: 7595 은(는) 현재 수익성이 없습니다.이익 마진 증가: 7595는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 7595은 수익성이 없으며 지난 5년 동안 손실이 연평균 20.7% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 7595의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 7595은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(7.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 7595는 현재 수익성이 없으므로 자본 수익률이 음수(-20.08%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/23 02:02종가2026/08/21 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharmigene, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Aug 15First half 2025 earnings released: NT$0.82 loss per share (vs NT$0.96 loss in 1H 2024)First half 2025 results: NT$0.82 loss per share (improved from NT$0.96 loss in 1H 2024). Revenue: NT$80.7m (up 68% from 1H 2024). Net loss: NT$41.3m (loss narrowed 15% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.64 loss per share (vs NT$1.60 loss in FY 2023)Full year 2024 results: NT$1.64 loss per share (further deteriorated from NT$1.60 loss in FY 2023). Revenue: NT$116.5m (down 12% from FY 2023). Net loss: NT$82.9m (loss widened 14% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 18First half 2024 earnings released: NT$0.96 loss per share (vs NT$0.66 loss in 1H 2023)First half 2024 results: NT$0.96 loss per share (further deteriorated from NT$0.66 loss in 1H 2023). Revenue: NT$47.9m (down 11% from 1H 2023). Net loss: NT$48.7m (loss widened 70% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 04Full year 2023 earnings released: NT$1.60 loss per share (vs NT$0.98 loss in FY 2022)Full year 2023 results: NT$1.60 loss per share (further deteriorated from NT$0.98 loss in FY 2022). Revenue: NT$132.7m (flat on FY 2022). Net loss: NT$72.6m (loss widened 70% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 14First half 2023 earnings released: NT$0.66 loss per share (vs NT$0.53 loss in 1H 2022)First half 2023 results: NT$0.66 loss per share (further deteriorated from NT$0.53 loss in 1H 2022). Revenue: NT$53.6m (down 2.7% from 1H 2022). Net loss: NT$28.7m (loss widened 25% from 1H 2022).
Reported Earnings • Apr 07Full year 2022 earnings released: NT$0.98 loss per share (vs NT$0.54 loss in FY 2021)Full year 2022 results: NT$0.98 loss per share (further deteriorated from NT$0.54 loss in FY 2021). Revenue: NT$133.8m (up 3.4% from FY 2021). Net loss: NT$42.7m (loss widened 82% from FY 2021).
New Risk • Jul 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$76m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$408.8m market cap, or US$12.7m).
New Risk • Jul 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$316.9m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$76m free cash flow). Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (NT$316.9m market cap, or US$9.83m).
Board Change • Mar 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Jan 30Pharmigene, Inc., Annual General Meeting, Jun 15, 2026Pharmigene, Inc., Annual General Meeting, Jun 15, 2026. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city Taiwan
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$86m free cash flow). Earnings have declined by 35% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (NT$149m revenue, or US$4.9m). Market cap is less than US$100m (NT$570.3m market cap, or US$18.8m).
Reported Earnings • Aug 15First half 2025 earnings released: NT$0.82 loss per share (vs NT$0.96 loss in 1H 2024)First half 2025 results: NT$0.82 loss per share (improved from NT$0.96 loss in 1H 2024). Revenue: NT$80.7m (up 68% from 1H 2024). Net loss: NT$41.3m (loss narrowed 15% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Board Change • Jun 23Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.64 loss per share (vs NT$1.60 loss in FY 2023)Full year 2024 results: NT$1.64 loss per share (further deteriorated from NT$1.60 loss in FY 2023). Revenue: NT$116.5m (down 12% from FY 2023). Net loss: NT$82.9m (loss widened 14% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
공고 • Mar 12Pharmigene, Inc., Annual General Meeting, Jun 03, 2025Pharmigene, Inc., Annual General Meeting, Jun 03, 2025. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city Taiwan
New Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$143m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (NT$127m revenue, or US$3.9m). Market cap is less than US$100m (NT$683.8m market cap, or US$20.8m).
Reported Earnings • Aug 18First half 2024 earnings released: NT$0.96 loss per share (vs NT$0.66 loss in 1H 2023)First half 2024 results: NT$0.96 loss per share (further deteriorated from NT$0.66 loss in 1H 2023). Revenue: NT$47.9m (down 11% from 1H 2023). Net loss: NT$48.7m (loss widened 70% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 04Full year 2023 earnings released: NT$1.60 loss per share (vs NT$0.98 loss in FY 2022)Full year 2023 results: NT$1.60 loss per share (further deteriorated from NT$0.98 loss in FY 2022). Revenue: NT$132.7m (flat on FY 2022). Net loss: NT$72.6m (loss widened 70% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
공고 • Apr 12Pharmigene, Inc., Annual General Meeting, Jun 24, 2024Pharmigene, Inc., Annual General Meeting, Jun 24, 2024.
New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.03b market cap, or US$32.6m).
New Risk • Oct 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.1m). Market cap is less than US$100m (NT$1.16b market cap, or US$35.9m).
Reported Earnings • Aug 14First half 2023 earnings released: NT$0.66 loss per share (vs NT$0.53 loss in 1H 2022)First half 2023 results: NT$0.66 loss per share (further deteriorated from NT$0.53 loss in 1H 2022). Revenue: NT$53.6m (down 2.7% from 1H 2022). Net loss: NT$28.7m (loss widened 25% from 1H 2022).
New Risk • Aug 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$681m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.06b market cap, or US$33.4m).
Reported Earnings • Apr 07Full year 2022 earnings released: NT$0.98 loss per share (vs NT$0.54 loss in FY 2021)Full year 2022 results: NT$0.98 loss per share (further deteriorated from NT$0.54 loss in FY 2021). Revenue: NT$133.8m (up 3.4% from FY 2021). Net loss: NT$42.7m (loss widened 82% from FY 2021).
Reported Earnings • Apr 12Full year 2021 earnings released: NT$0.54 loss per share (vs NT$0.33 loss in FY 2020)Full year 2021 results: NT$0.54 loss per share (down from NT$0.33 loss in FY 2020). Revenue: NT$129.4m (up 28% from FY 2020). Net loss: NT$23.4m (loss widened 109% from FY 2020).